4.7 Article

Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria

Journal

DIABETES CARE
Volume 41, Issue 7, Pages 1493-1500

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc17-2392

Keywords

-

Funding

  1. Danish Research Foundation
  2. Danish Agency for Science, Technology and Innovation [413500023]

Ask authors/readers for more resources

OBJECTIVEType 2 diabetes is a common risk factor for the development of chronic kidney disease (CKD). Enhanced de novo collagen type VI (COL VI) formation has been associated with renal fibrosis and CKD. We investigated the hypothesis that PRO-C6, a product specifically generated during COL VI formation, is prognostic for adverse outcomes in patients with type 2 diabetes and microalbuminuria.RESEARCH DESIGN AND METHODSIn a prospective, observational study, we measured PRO-C6 in the serum (S-PRO-C6) and urine (U-PRO-C6) of 198 patients with type 2 diabetes and microalbuminuria without symptoms of coronary artery disease. Patients were followed for a median of 6.5 years, and end points were a composite of cardiovascular events (n = 38), all-cause mortality (n = 26), and reduction of estimated glomerular filtration rate (eGFR) of >30% (disease progression [n = 42]). Cox models were unadjusted and adjusted for the conventional risk factors of sex, age, BMI, systolic blood pressure, LDL cholesterol, smoking, HbA(1c), plasma creatinine, and urinary albumin excretion rate.RESULTSDoubling of S-PRO-C6 increased hazards for cardiovascular events (hazard ratio 3.06 [95% CI 1.31-7.14]), all-cause mortality (6.91 [2.96-16.11]), and disease progression (4.81 [1.92-12.01]). Addition of S-PRO-C6 to a model containing conventional risk factors improved relative integrated discrimination by 22.5% for cardiovascular events (P = 0.02), 76.8% for all-cause mortality (P = 0.002), and 53.3% for disease progression (P = 0.004). U-PRO-C6 was not significantly associated with any of the outcomes.CONCLUSIONSS-PRO-C6 generated during COL VI formation predicts cardiovascular events, all-cause mortality, and disease progression in patients with type 2 diabetes and microalbuminuria.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Transplantation

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Jennifer B. Green, Amy K. Mottl, George Bakris, Hiddo J. L. Heerspink, Johannes F. E. Mann, Janet B. McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal

Summary: This study aims to investigate the efficacy of dual therapy with finerenone and an SGLT2i in reducing chronic kidney disease and type 2 diabetes. The results will provide important insights for improving treatment methods for kidney disease and cardiovascular risks.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use

Peter Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Vivian Fonseca, Guillermo E. Umpierrez, Maria Luiza Caramori, Amer Joseph, Marc Lambelet, Robert Lawatscheck, George L. Bakris

Summary: This study investigated the effect of GLP-1RA use on the outcomes of patients with CKD and T2D treated with finerenone. The results showed that the use of GLP-1RA did not affect the cardiorenal benefits of finerenone.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: A cross-sectional 68 Ga-RGD-PET study

Jens Christian Laursen, Ida Kirstine Bull Rasmussen, Emilie Hein Zobel, Philip Hasbak, Lene Holmvang, Christian Stevns Hansen, Bernt Johan von Scholten, Marie Frimodt-Moller, Peter Rossing, Tine Willum Hansen, Andreas Kjaer, Rasmus Sejersten Ripa

Summary: Cardiac angiogenesis assessed by Ga-68-RGD PET was similar in type 2 diabetes and non-diabetic controls, and was not associated with kidney function or other risk factors.

DIABETIC MEDICINE (2023)

Article Medicine, General & Internal

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

Sankar D. Navaneethan, Sophia Zoungas, M. Luiza Caramori, Juliana C. N. Chan, Hiddo J. L. Heerspink, Clint Hurst, Adrian Liew, Erin D. Michos, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Jonathan C. Craig, David J. Tunnicliffe, Marcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing, Ian H. de Boer, Kamlesh Khunti

Summary: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline. The guideline was updated based on reviewing new evidence and using the GRADE approach to assess evidence and develop consensus practice points. The recommendations were updated in the areas of comprehensive care and glucose-lowering therapies, while recommendations in the areas of glycemic monitoring, lifestyle interventions, and management approaches remained unchanged.

ANNALS OF INTERNAL MEDICINE (2023)

Article Transplantation

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Peter Rossing, Florian M. M. Baeres, George Bakris, Heidrun Bosch-Traberg, Mette Gislum, Stephen C. L. Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F. E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine Tuttle, Richard Pratley, FLOW Steering Comm, FLOW Trial Investigators

Summary: This study aims to investigate the effects of semaglutide on kidney outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The participants were found to be mostly at high risk for CKD progression. The study is expected to be completed in late 2024.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study

Suvanjaa Sivalingam, Victor Soendergaard Wasehuus, Viktor Rotbain Curovic, Martin Baek Blond, Tine W. Hansen, Frederik Persson, Peter Rossing

Summary: The combination of semaglutide and empagliflozin did not lead to changes in UACR, GFR, blood pressure, body weight, or plasma renin levels in individuals with T2D and albuminuria. However, semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes

Viktor Rotbain Curovic, Morten B. Houlind, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Juliette Tavenier, Jesper Eugen-Olsen, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Peter Rossing, Hiddo J. L. Heerspink

Summary: The effect of four different drug classes on suPAR levels in people with type 1 and type 2 diabetes was evaluated. The study showed no overall effect of the drugs on suPAR levels, but individualized treatment significantly reduced suPAR levels.

DIABETES OBESITY & METABOLISM (2023)

Letter Endocrinology & Metabolism

Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Jens Christian Laursen, Viktor Rotbain Curovic, Marjolein Y. A. M. Kroonen, Niels Jongs, Emilie H. Zobel, Tine W. Hansen, Marie Frimodt-Moller, Gozewijn D. Laverman, Adriaan Kooy, Frederik Persson, Hiddo J. L. Heerspink, Christian Stevns Hansen, Peter Rossing

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill

Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Article Endocrinology & Metabolism

Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark

Zeinab Schafer, Andreas Mathisen, Trine Rolighed Thomsen, Peter Rossing, Klaus Kirketerp-Moller

Summary: This study conducted a cohort analysis on 309,116 patients with type 2 diabetes and found that GLP-1 agonist treatment significantly reduces the risk of lower extremity amputations, particularly among middle-income patients.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Review Endocrinology & Metabolism

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Vikas S. Sridhar, Christine P. Limonte, Per-Henrik Groop, Hiddo J. L. Heerspink, Richard E. Pratley, Peter Rossing, Jay S. Skyler, David Z. I. Cherney

Summary: The current management of CKD in type 1 diabetes focuses on blood sugar control, inhibiting the renin-angiotensin system and optimizing risk factors. However, individuals with type 1 diabetes and CKD still face elevated risks for kidney and cardiovascular events. Novel therapies used in type 2 diabetes, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, have shown potential kidney and heart protection. Applying these therapies to individuals with type 1 diabetes for the prevention of CKD is of great importance.

DIABETOLOGIA (2023)

Article Urology & Nephrology

Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen

Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Article Cardiac & Cardiovascular Systems

Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies

Hashmat Sayed Zohori Bahrami, Peter Godsk Jorgensen, Jens Dahlgaard Hove, Ulrik Dixen, Tor Biering-Sorensen, Peter Rossing, Magnus T. Jensen

Summary: Cardiovascular disease is the leading cause of death in type 1 and type 2 diabetes patients. The myocardial performance index (MPI), which reflects left ventricular function, has not been evaluated for its prognostic value in diabetes populations. This study evaluated two prospective cohort studies and found that MPI is associated with major adverse cardiovascular events and heart failure, particularly in type 1 diabetes patients, and improves prediction in this group.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2023)

Article Gastroenterology & Hepatology

Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease

Morten A. Karsdal, Kate Hallsworth, Jadine Scragg, Diana J. Leeming, Ida F. Villesen, Leah Avery, Laura Haigh, Olivier Govaere, Sarah Wichmann, Guy Taylor, Sophie Cassidy, Stuart Mcpherson, Quentin M. Anstee

Summary: The amount of fibroblast activity in patients with NAFLD can be defined by circulating biomarkers of collagen formation. The high-risk, high-fibrogenesis patient endotype with greater fibroblast activity exhibited a marked reduction in collagen fibrogenesis with a very low-calorie diet intervention, while fibrogenesis remained unchanged in the low activity group. The quantification of fibrogenesis biomarkers at baseline can predict the likelihood of treatment response.

HEPATOLOGY COMMUNICATIONS (2023)

Article Urology & Nephrology

Indicators of Kidney Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease Treated With Dulaglutide

Katherine R. R. Tuttle, Jonathan M. Wilson, Yanzhu Lin, Hui-Rong Qian, Federica Genovese, Morten A. Karsdal, Kevin L. L. Duffin, Fady T. Botros

Summary: In the AWARD-7 study, once-weekly dulaglutide treatment in patients with type 2 diabetes and chronic kidney disease demonstrated a slower decline in eGFR and a reduction in urine albumin/creatinine ratio compared to insulin glargine. This exploratory analysis found that dulaglutide treatment was associated with lower levels of PRO-C6 and higher levels of C3M, indicating reduced type VI collagen formation and increased type III collagen degradation, suggesting a potential mechanism for reducing kidney fibrosis.

AMERICAN JOURNAL OF NEPHROLOGY (2023)

No Data Available